HUP0105365A2 - Orális adagolás után gliklazid tartós felszabadítására alkalmazható mátrixtabletta - Google Patents

Orális adagolás után gliklazid tartós felszabadítására alkalmazható mátrixtabletta

Info

Publication number
HUP0105365A2
HUP0105365A2 HU0105365A HUP0105365A HUP0105365A2 HU P0105365 A2 HUP0105365 A2 HU P0105365A2 HU 0105365 A HU0105365 A HU 0105365A HU P0105365 A HUP0105365 A HU P0105365A HU P0105365 A2 HUP0105365 A2 HU P0105365A2
Authority
HU
Hungary
Prior art keywords
gliclazide
oral administration
controlled release
core tablet
methylcellulose
Prior art date
Application number
HU0105365A
Other languages
English (en)
Inventor
Bruno Huet De Barochez
Louis Martin
Patrick Wuthrich
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9541429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0105365(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of HUP0105365A2 publication Critical patent/HUP0105365A2/hu
Publication of HUP0105365A3 publication Critical patent/HUP0105365A3/hu
Publication of HU225693B1 publication Critical patent/HU225693B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A tal lm ny t rgya gliklazid tartós felszabadít s ra alkalmazható mtrixtabletta, amely a gliklazid mellett legal bb egy cellulózpolimervegyület és glükózszirup kombin ciój t tartalmazza. E kombin ció agliklazid felszabadít s nak a szab lyz s t, valamint a gliklazid oldódsi kinetik j nak az oldók"zeg pH-v ltoz saival szembeniérzéketlenségét teszi lehetővé. A cellulóz polimer vegyület legal bbegy (hidroxipropil) metilcellulózból, előny"sen 4000 cP viszkozit sú(hidroxipropil)metilcellulóz és 100 cP viszkozit sú(hidroxipropil)metilcellulóz keverékéből ll. Glükózszirupként atablett ban előny"sen maltodextrin haszn lható. A tal lm ny szerinti mtrixtablett t nedves granul l si elj r ssal vagy k"zvetlen sajtol sielj r ssal llítj k elő. Ó
HU0105365A 1999-02-01 1999-10-15 Core tablet for controlled release of gliclazide after oral administration HU225693B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9901082A FR2788981B1 (fr) 1999-02-01 1999-02-01 Comprime matriciel permettant la liberation prolongee de gliclazide apres administration par voie orale
PCT/FR1999/002520 WO2000018373A1 (fr) 1999-02-01 1999-10-15 Comprime matriciel permettant la liberation prolongee de gliclazide apres administration par voie orale

Publications (3)

Publication Number Publication Date
HUP0105365A2 true HUP0105365A2 (hu) 2002-04-29
HUP0105365A3 HUP0105365A3 (en) 2002-11-28
HU225693B1 HU225693B1 (en) 2007-06-28

Family

ID=9541429

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105365A HU225693B1 (en) 1999-02-01 1999-10-15 Core tablet for controlled release of gliclazide after oral administration

Country Status (37)

Country Link
US (1) US6733782B1 (hu)
EP (1) EP1148871B1 (hu)
JP (2) JP4716465B2 (hu)
KR (1) KR100491600B1 (hu)
CN (1) CN1160061C (hu)
AP (1) AP1243A (hu)
AT (1) ATE296621T1 (hu)
AU (1) AU764516B2 (hu)
BR (1) BR9917012A (hu)
CA (1) CA2273420C (hu)
CZ (1) CZ298196B6 (hu)
DE (1) DE69925639T2 (hu)
DK (1) DK1148871T3 (hu)
EA (1) EA002625B1 (hu)
EE (1) EE05024B1 (hu)
ES (1) ES2241323T3 (hu)
FR (1) FR2788981B1 (hu)
GE (1) GEP20053501B (hu)
HK (1) HK1043049A1 (hu)
HR (1) HRP20010632B1 (hu)
HU (1) HU225693B1 (hu)
ID (1) ID30225A (hu)
IL (2) IL144246A0 (hu)
ME (1) ME00436B (hu)
NO (1) NO329951B1 (hu)
NZ (1) NZ512878A (hu)
OA (1) OA11756A (hu)
PL (1) PL194505B1 (hu)
PT (1) PT1148871E (hu)
RS (1) RS50121B (hu)
SA (1) SA00210446B1 (hu)
SK (1) SK285209B6 (hu)
TR (1) TR200102002T2 (hu)
UA (1) UA68414C2 (hu)
WO (1) WO2000018373A1 (hu)
YU (1) YU53101A (hu)
ZA (1) ZA200106305B (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
SE0200539D0 (sv) * 2002-02-25 2002-02-25 Metcon Medicin Ab Granulation process and starch granulate
CN100391459C (zh) * 2003-05-26 2008-06-04 沈阳药科大学 甲磺酸多沙唑嗪缓释制剂
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
EP1741435A4 (en) * 2004-04-29 2009-11-11 Lotus Pharmaceutical Co Ltd ORAL VAPORS WITH MODIFIED RELEASE AND METHOD OF MANUFACTURING THEM
CN100413491C (zh) * 2004-06-14 2008-08-27 北京德众万全药物技术开发有限公司 一种难溶性药物的控释制剂
WO2006061697A1 (en) * 2004-12-06 2006-06-15 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
EP1946780B1 (en) * 2005-11-11 2012-01-11 Asahi Kasei Chemicals Corporation Controlled release solid preparation
US20080286343A1 (en) * 2007-05-16 2008-11-20 Dzenana Cengic Solid form
TR200704897A1 (tr) * 2007-07-13 2009-02-23 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Uzatılmış salım sağlayan gliklazid formülasyonları@
TR200708938A2 (tr) * 2007-12-26 2008-11-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salım sağlayan gliklazid tablet
ITFI20080016A1 (it) * 2008-02-05 2009-08-06 Valpharma Sa Formulazioni farmaceutiche orali contenenti gliclazide.
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
WO2009140279A2 (en) * 2008-05-12 2009-11-19 Concert Pharmaceuticals, Inc. Sulfonyl urea compounds
EP2181705A1 (en) 2008-10-31 2010-05-05 Disphar International B.V. Sustained-release formulation of gliclazide
KR20110117216A (ko) * 2009-03-03 2011-10-26 제노포트 인코포레이티드 Ｒ-바클로펜 전구약물의 서방형 경구 투약 형태
JP5669837B2 (ja) 2010-06-16 2015-02-18 帝人ファーマ株式会社 放出制御型の有核錠剤
EP2468268B1 (en) 2010-12-21 2017-12-13 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Combination composition of vildagliptin and gliclazide
TR201107482A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç San.Ve Ti̇c.A.Ş. Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu.
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2013124832A2 (en) * 2012-02-24 2013-08-29 Ranbaxy Laboratories Limited Stabilized controlled-release pharmaceutical composition comprising gliclazide
EP2958548A1 (en) * 2013-02-19 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. A production process for gliclazide formulations
ITFI20130184A1 (it) * 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
ITMI20132065A1 (it) * 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di curcumina nel trattamento delle malattie intestinali
MX2017000840A (es) 2014-07-18 2017-05-04 Sanofi Sa Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
WO2016042568A1 (en) * 2014-09-16 2016-03-24 Suresh Pareek Extended release formulation of gliclazide
CN111329841B (zh) * 2020-03-04 2021-11-19 山东鲁抗医药集团赛特有限责任公司 格列齐特缓释片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1449404A (en) * 1973-03-30 1976-09-15 Science Union & Cie N-arylsulphonyl urea derivatives
US4056623A (en) * 1975-03-05 1977-11-01 Science Union Et Cie, Societe Francaise De Recherche Medicale Methods of treating animals suffering from hyperlipidemia using certain N-phenyl sulphonyl-N'-(3-azabicycloalkyl) ureas
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
DE4336159A1 (de) * 1993-10-22 1995-04-27 Kurt Heinz Prof Dr Bauer Hochwirksame, den Wirkstoff schnell oder kontrolliert freisetzende Zubereitungsformen von Sulfonylharnstoffen und Verfahren zu deren Herstellung
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.

Also Published As

Publication number Publication date
TR200102002T2 (tr) 2002-01-21
NZ512878A (en) 2002-05-31
KR100491600B1 (ko) 2005-05-27
NO20013757L (no) 2001-08-09
JP2002525310A (ja) 2002-08-13
ZA200106305B (en) 2002-07-31
IL144246A (en) 2006-12-10
ME00436B (me) 2011-10-10
EP1148871A1 (fr) 2001-10-31
EE05024B1 (et) 2008-06-16
DK1148871T3 (da) 2005-09-19
YU53101A (sh) 2004-05-12
DE69925639T2 (de) 2006-04-27
NO20013757D0 (no) 2001-07-31
UA68414C2 (en) 2004-08-16
AP1243A (en) 2004-02-02
ID30225A (id) 2001-11-15
PL194505B1 (pl) 2007-06-29
US6733782B1 (en) 2004-05-11
CN1160061C (zh) 2004-08-04
SK10952001A3 (sk) 2001-12-03
FR2788981B1 (fr) 2002-05-17
PL356707A1 (en) 2004-06-28
HU225693B1 (en) 2007-06-28
EP1148871B1 (fr) 2005-06-01
OA11756A (en) 2005-07-19
HRP20010632B1 (en) 2006-02-28
NO329951B1 (no) 2011-01-31
CN1342068A (zh) 2002-03-27
JP2008179649A (ja) 2008-08-07
SA00210446B1 (ar) 2006-10-11
HK1043049A1 (en) 2002-09-06
FR2788981A1 (fr) 2000-08-04
EA002625B1 (ru) 2002-06-27
EE200100398A (et) 2002-10-15
HUP0105365A3 (en) 2002-11-28
BR9917012A (pt) 2002-04-16
DE69925639D1 (de) 2005-07-07
ES2241323T3 (es) 2005-10-16
HRP20010632A2 (en) 2005-02-28
PT1148871E (pt) 2005-08-31
SK285209B6 (sk) 2006-08-03
AP2001002212A0 (en) 2001-09-30
AU764516B2 (en) 2003-08-21
JP4716465B2 (ja) 2011-07-06
CA2273420A1 (fr) 2000-08-01
AU6098299A (en) 2000-04-17
RS50121B (sr) 2009-03-25
CZ298196B6 (cs) 2007-07-18
CA2273420C (fr) 2002-07-09
WO2000018373A1 (fr) 2000-04-06
ATE296621T1 (de) 2005-06-15
KR20010093307A (ko) 2001-10-27
EA200100827A1 (ru) 2002-02-28
IL144246A0 (en) 2002-05-23
CZ20012661A3 (cs) 2001-11-14
GEP20053501B (en) 2005-05-10

Similar Documents

Publication Publication Date Title
HUP0105365A2 (hu) Orális adagolás után gliklazid tartós felszabadítására alkalmazható mátrixtabletta
US6177102B1 (en) Once daily analgesic tablet
NO20070719L (no) Tablettformulering med forlenget frigivelse som inneholder pramipeksol eller et farmasoytisk akseptabelt salt derav, fremgangsmate for fremstilling av den og anvendelse derav
HRP20100111T1 (hr) Nova formulacija doze
TW200608975A (en) Pharmaceutical compositions
UA41887C2 (uk) Фармацевтична композиція, що зазнає ерозію
AU2017220971A1 (en) Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof
PT923934E (pt) Formulacao de matriz de libertacao modificada de cefaclor e cefalexina
HUP0400382A2 (hu) Késleltetett leadású készítmény és eljárás annak előállítására
GR1003658B (el) Δισκιο μητρας που καθιστα δυνατη την παρατεταμενη απελευθερωση της τριμεταζιδινης μετα χορηγηση δια της στοματικης οδου
US6150410A (en) pH independent extended release pharmaceutical formulation
JP3110794B2 (ja) １，４−ジヒドロピリジン誘導体を含有する製剤
CA2502731A1 (en) Sustained release composition for oral administration of drugs
NO20044810L (no) Farmasoytisk formulering med oyeblikkelig frigjoring
EP1146864B1 (en) Ph independent extended release pharmaceutical formulation
JPS63270624A (ja) ニコランジル安定化製剤の製造方法
JP2711528B2 (ja) ロキソプロフェン製剤
JP2000026292A5 (hu)
JP2004522780A5 (hu)
HUP0100850A2 (hu) Fokozott biológiai hasznosulású, molekulárisan diszpergált készítmény
EE9600202A (et) Toimeaine pärsitud vabanemisega karbamasepiini ravimvorm
JPH05139973A (ja) ニフエジピン含有固形製剤の製造方法
IS6504A (is) Ný galensk lyfjablanda með hægri losun á molsidómíni
WO2004026261A3 (en) Composition containing ribavirin and use thereof
CN105581988A (zh) 一种缬沙坦的口腔崩解片